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John Le Gall,1 Zhezhen Jin,2 Joseph Schwartz,3 Deirdre Duffy,4 Carmella van de Ven,4
Sandra Foley,4 Ria Hawks,1 Erin Morris,4 Lee Ann Baxter-Lowe,5 Mitchell S. Cairo4,6,7,8,9Children with high-risk acute myelogenous leukemia (AML) (induction failure [IF], refractory relapse [RR],
third complete remission [CR3]) have dismal outcomes. Over 80% of AML patients express CD33, a target
of gemtuzumab ozogamicin (GO). GO is an active drug in childhood AML but has not been studied in a mye-
loablative conditioning regimen. We sought to determine the safety of GO in combination with busulfan/
cyclophosphamide (Bu/Cy) conditioning before allogeneic hematopoietic stem cell transplantation (alloSCT).
GO was administered on day214 at doses of 3.0, 4.5, 6.0, and 7.5 mg/m2, busulfan on days27,26,25,24
(12.8-16.0 mg/kg), and cyclophosphamide on days23 and22 (60 mg/kg/day). GVHD prophylaxis consisted
of tacrolimus and mycophenolate mofetil. We enrolled 12 patients: 8 IF, 3 RR, 1 CR3; median age: 3 years
(1-17); median follow-up: 1379 days (939-2305). Nine received umbilical cord blood (UCB), 2 matched un-
related donors (MUDs) and 1 HLA-matched sibling donor: 3 patients each at GO doses of 3.0, 4.5, 6.0, or 7.5
mg/m2. No dose-limiting toxicities secondary to GO were observed. Day 100 treatment-related mortality
(TRM) was 0%. Myeloid and platelet engraftment was observed in 92% and 75% of patients at median day
22 (12-40) and 42 (21-164), respectively. Median day130 donor chimerism was 99% (85%-100%). The prob-
ability of grade II-IV acute graft-versus-host disease (aGVHD) was 42% and chronic GVHD (cGVHD) was
28%. One-year overall survival (OS) and event-free survival (EFS) was 50% (95% confidence interval [CI],
20.8-73.6). GO combined with Bu/Cy regimen followed by alloSCT is well tolerated in children with poor-
risk AML. GO at 7.5 mg/m2 in combination with Bu/Cy is currently being tested in a phase II study.
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regimenINTRODUCTION who underwent allogeneic stem cell transplantationAcute myelogenous leukemia (AML) is responsible
for.30%of all deaths from childhood acute leukemias
[1]. The 5-year event-free survival (EFS) rate for child-
hood AML is approximately 50% [2-4]. The outcome
of children with poor-risk AML remains dismal. Mi-
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free survival following alloSCT. Novel conditioning
regimens are needed in this subgroup of poor-risk pa-
tients with AML. There have been no studies reported
that use gemtuzumab ozogamicin (GO) in combina-
tion withmyeloablative conditioning (MAC) before al-
loSCT. We hypothesized that the addition of GO in
combination with busulfan/cyclophosphamide (Bu/
Cy)MAC followed by alloSCT in children and adoles-
cents with poor-risk CD331 AML/myelodysplastic
syndrome would be safe and well tolerated.METHODS
Eligibility Criteria
Patients were required to be \21 years of age.
Disease-specific requirements included AML-PIF,
AML in first, second, or third relapse, or AML$CR3.
Leukemia cells had to express a minimum of .10%
CD33 positivity. Patients who received GO within
30 days before starting conditioning for alloSCT were
ineligible. All patients signed an informed consent
approved by the institutional review board, and all
researchprotocolswere in compliancewith theDeclara-
tion of Helsinki.
Treatment Plan
Patients received sinusoidal obstruction syndrome
(SOS) prophylaxis with enoxaparin sodium on day
215 to day 121. Patients received GO on day 214
intravenously (i.v.) 1. Bu (i.v.) was administered at
a dose of 3.2-4 mg/kg/day divided every 12 hours on
day 27 to day 24. On days 23 and 22, patients
received cyclophosphamide (60 mg/kg/day). Patients
with MUDs and umbilical cord blood (UCB) donors
also received rabbit antithymocyte globulin (2 mg/
kg/day) from day 25 to day 22.
Patients received GO on day214 at the dose of 3.0
mg/m2/dose (dose level 1), 4.5 mg/m2/dose (dose level
2), 6 mg/m2/dose (dose level 3), or 7.5 mg/m2/dose
(dose level 4); the dose was assigned at study entry.
Starting dose of GO was 3.0 mg/m2/dose as this dose
was tolerated well in combination with other cytotoxic
chemotherapy in young adults with AML [7]. The tim-
ing of GO administration was based on a half-life of 67
hours [8]. In the absence of pharmacokinetic studies,
we anticipated that serum levels of GO would be
very low on the day of stem cell infusion as GO would
have completed 5 half-lives (335 hours) before day 0.
Escalation was planned in groups of 3 subjects with
an additional 3 subjects to be added at the first
indication of dose-limiting toxicity (DLT). The defi-
nition of DLT of GO was either any grade IV nonhe-
matologic toxicity probably or definitely related to
GO, any grade III nonhematologic toxicity probably
or definitely related to GO that did not resolve in 7days, or death related to or unresponsive to treatment
to severe SOS. The Baltimore criteria were used to as-
sess SOS [9]. DLTs were followed through day 130.
Graft-versus-Host Disease (GVHD) Prophylaxis
Acute GVHD (aGVHD) prophylaxis consisted of
tacrolimus, starting onday21, andmycophenolatemo-
fetil, as we have previously described [10,11]. Patients
receiving alloSCT from MUDs received additional
methotrexate (5 mg/m2/dose i.v.) on days 11,13,16,
and 111. Mycophenolate mofetil taper was stopped
on day 160 in patients with more than grade I
aGVHD followed by tacrolimus taper over 8 weeks.
Acute GVHD and chronic GVHD (cGVHD) were
scored according to previously published guidelines
[12]. Infection prophylaxis, supportive care, engraft-
ment, chimerism, and HLA typing were performed as
per our institutional guidelines [13-16].
Statistics
The product-limit method of Kaplan-Meier was
used to determine the probabilities of myeloid and
platelet engraftment, aGVHD and cGVHD, relapse,
EFS, and overall survival (OS) [17]. EFS was defined
as death because of any cause or relapse, andOSwas de-
fined as surviving patients with and without leukemia.RESULTS
Patients Demographic and Disease Status
In this single-center phase I pilot study, 12 patients
were enrolled at a median age of 3 years (range: 1-
17 years). Median follow-up for surviving patients
was 1379 days (range: 939-2305). Sixty-six percent (8
of 12) had induction failure (IF) (7 PIF and 1 reinduc-
tion failure), 25% (3 of 12) of patients were trans-
planted in relapse, and 8% (1 of 12) of patients were
transplanted in CR3. Disease status at alloSCT was
CR1, 7 of 12 (58%); RR, 3 of 12 (25%); and CR2, 1
of 12 (8%) and CR3 (8%). The complete demograph-
ics and key outcome variables are depicted in Table 1.
GO Dose Escalation and Toxicities
Three patients each, at GO doses of 3, 4.5, 6, and
7.5 mg/m2 were treated.
Patients were monitored for 30 days following
alloSCT for nonhematologic toxicity definitely, prob-
ably, or possibly related to GO. Two patients had
infusion-related fever, and 1 patient had transient
grade I hypotension. Five patients had blood stream
bacterial infections, of which 3 patients developed clin-
ical sepsis. During the first 30 days following alloSCT,
4 patients developed hyperbilirubinemia (.2 mg/dL),
the highest level of bilirubin among this cohort of chil-
dren was 4.1 mg/dL, 2 patients were diagnosed to have
Table 1. Patient Demographics, Hematologic Reconstitution, Graft-versus-Host Disease, and Outcome of Children following GO d Bu/Cy Regimen followed by alloSCT
ID
GO Dose
(mg/m2)
Age
(Years)/Sex Disease
Cytogenetic
Abnormalities
Indication
for AlloSCT
Disease
Status at
AlloSCT
Donor
Source/HLA
Match
Prior
GO
SOS*/Max
Bilirubin
Myeloid
Engraftment
(Day+)
Pla let
Engra ment
(D +)
Max
Chimerism (%)
aGVHD
Grade
cGVHD
Grade Outcome
1 3.0 1/F AML/NK t(1;16)
del(16)
PIF CR1 4/6 UCB No Yes/3.9 21 1 100 Grade II None Alive
day +1955
2 3.0 4/F MDS/AML der(7)
inv (p13p22)add(p22),
t(12;22)
CR3 CR3 4/6 UCB No No/0.8 31 1 4 95 Grade III Yes Dead
day +357
3 3.0 17/M AML-M0 None PIF CR1 6/6 MRD Yes No/1.6 12 2 100 None Yes Dead
day +270
4 4.5 2/F AML M4 52XX, Trisomy
16 and 21
R/R R/R 6/6 UCB No No/1.3 22 2 100 None None Alive
day + 1669
5 4.5 10/F MDS/AML Monosomy 7 R/R R/R 5/6 UCB No No/4.1 40 D 99 Grade III No Dead
day +229
6 4.5 2/M AML-M0 11q23 RIF CR2 6/6 UCB Yes No/1.0 22 0 100 None No Dead
day +184
7 6.0 11/M AML-M1 Trisomy 6 PIF CR1 10/10 MUD No No/1.4 12 7 100 Grade III Yes Alive
day +1089
8 6.0 15/F AML-M5 11q23 R/R R/R 4/6 UCB No Yes/3.7 DR D 93 None No Dead
day +206
9 6.0 2/F AML M0 11q23 PIF CR1 5/6 UCB No No/0.7 32 8 99 Grade I No Alive
day +969
10 7.5 2/M APML t(15:17) PIF CR1 6/6 UCB Yes No/0.9 17 9 98 None No Alive
day +696
11 7.5 12/M MDS/AML Monosomy 7 PIF CR1 10/10 MUD No No/2.9 26 D 100 Grade II Yes Alive
day +589
12 7.5 1/F AML-M4 None PIF CR1 5/6 UCB Yes No/1.0 35 6 99 Grade II No Dead
day + 473
M indicates male; F, female; HLA, human leukocyte antigen; A, alive; D, dead; RIF, reinduction failure; R/R, refractory relapse; DR, did not recover; MDS, yelodysplastic syndromes; Max bilirubin, maximum bilirubin
(mg/dL) from day 215 to day +30 after alloSCT.
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Figure 1. Cumulative probability of EFS and OS in patients receiving
GO in combination with a myeloablative conditioning regimen and
alloSCT in children with high-risk CD331 AML.
Biol Blood Marrow Transplant 18:309-329, 2012 327Gemtuzumab and Allogeneic SCT in Childhood AMLmoderate SOS, which resolved with fluid restriction
and diuretics, and 1 patient each developed hyper-
bilirubinemia secondary to liver aGVHD that was
diagnosed with liver biopsy (pt #5) and fungal sepsis
(Malassezia furfur) (pt #11), hyperbilirubinemia and
fungal sepsis resolved after antifungal therapy. Four
patients who received GO before GO plus MAC al-
loSCT did not develop hyperbilirubinemia (\2 mg/
dL) or any other major toxicities. NoDLTs secondary
to GO were observed. The day 1100 treatment-
related mortality (TRM) was 0%.
Hematologic Reconstitution and GVHD after
GO and Myeloablative alloSCT
Myeloid engraftment was observed in 92% of
patients at a median of 22 days (range: 12-40), and
75% of patients engrafted platelets at a median of
42 days (range: 21-164). One patient (515-08) did
not achieve myeloid and platelet engraftment. How-
ever, the donor chimerism was 93% on day 130.
This patient died because of disease relapse.
The cumulative incidence of developing grade
II-IV aGVHD and cGVHD was 42% and 28%,
respectively.
Relapse and Survival
One-year OS and EFS was 50% (95% confidence
interval [CI], 20.8-73.6) (Figure 1). Seven of 12 pa-
tients relapsed (5 died from progressive disease, 2 are
alive with 1 receiving palliative care and 1 with no ev-
idence of disease after additional chemotherapy and
donor lymphocyte infusion), and only 1 patient died
of TRM secondary to cGVHD.DISCUSSION
This is the first successful report either in pediatric
or adult recipients where GO was safely combined
with a MAC (Bu/Cy) before alloSCT. In this study,
we demonstrated that in a phase I dose escalation,
GO either at 6.0 or 7.5 mg/m2/dose administered on
day 214 in combination with MAC with Bu (12.8-
16.0 mg/kg) and Cy (120 mg/kg) was safe and well tol-
erated in children and adolescents with poor-risk
AML. Importantly, there were no DLTs related to
GO and despite the fact that 75% received UCB trans-
plantation, the probability of day 1100 TRM was
zero. There have been 2 previous reports of combining
GO with reduced-intensity conditioning regimens be-
fore alloSCT in adults with poor-risk AML [18,19].
de Lima et al. [19] demonstrated that the combination
of GO (day212) at a dose of 4 mg/m2 in combination
with fludarabine (120 mg/m2) and melphalan (140
mg/m2) was too toxic before alloSCT (50% toxicity
rate) and decreased the dose of GO to 2 mg/m2 and
demonstrated a reduction of toxicity to 18%. Theday 100 TRM was 15% in this adult AML alloSCT
study. In contrast, Bornhauser et al. [18] administered
GO in 2 divided doses (6 mg/m2 on day226 and 3mg/
m2 on day 214) before a variety of reduced-intensity
conditioning regimens and alloSCT in adults with
poor-risk AML. In this study, the day 221 dose of
GO served more as a reinduction agent and less so as
part of the conditioning regimen before alloSCT
[18]. In the Bornhauser study, the day 100 TRM was
22% and there was 1 case of moderate SOS. However,
in neither of these 2 adult AML alloSCT trials was GO
combined with a MAC regimen, which was the major
obstacle of the current reported study.
The optimal dose and schedule of GO in the
induction, consolidation, and reinduction of both chil-
dren and adults with AML is currently unknown. In
children and adolescents, the single-agent dose of
GO in relapsed AML has been reported by Arceci
et al. [20] to be 6 mg/m2, and by Zwaan et al. [21] to
be 7.5 mg/m2, respectively. When GO is administered
in combination with cytarabine or mitoxantrone
conditioning regimens for reinduction with relapsed/
refractory AML in children, the dose has ranged from
2-3 mg/m2 as a single dose [22], to 3 mg/m2 on days
1, 4, and 7 [23], respectively. However, this is the first
study in children and adolescents to combine GO
with a MAC before alloSCT, and we demonstrated
that GO from 3.0 to 7.5 mg/m2 was well tolerated
and safe in combination with Bu/Cy before alloSCT.
Wadleigh et al. [24] demonstrated there was an in-
creased risk of severe SOS if GO was administered
within 3.5 months before alloSCT. In the present
study, 4 of 12 patients had prior GO before condition-
ing withGO and only 2 of 12 developedmoderate SOS
(maximum bilirubin 4.1 mg/dL), which resolved with
328 Biol Blood Marrow Transplant 18:309-329, 2012P. Satwani et al.fluid restriction and diuretics. The lesser-than-
expected SOS could be potentially related to lower-
dose methotrexate used for GVHD prophylaxis or
SOS prophylaxis with enoxaparin [25] and strict mon-
itoring of busulfan levels after the first dose. However,
we need a larger cohort of patients to definitively ascer-
tain the risk and severity of SOS.
Although the role of alloSCT in children and
adolescents with newly diagnosed AMLhas undergone
changes in the last 10 to 15 years [26], its role in poor-
risk AML includingPIFs, RR, and$CR3has remained
vitally important [27,28]. Bunin et al. [5] reported, in
children and adolescents (#18 years) with AML and
either PIF (n 5 36) or RR (n 5 90) treated with MAC
and an unrelated adult donor bone marrow graft,
a 5-year leukemia-free survival and OS of 12% and
20%, respectively. Similarly, in the National Heart,
Lung, Blood Institute cord blood transplantation
study, Wall et al. [29] reported an estimated 35% OS
in children and adolescents with PIF or relapsed
AML following MAC and UCBT. Michel et al. [30]
reported for the EurocordGroup, in children and ado-
lescents with CR3 or relapsed AML, an estimated
#20% 3-year leukemia-free survival following MAC
and UCB transplantation. Duval et al. [31], reporting
for the Center for International Blood and Marrow
Transplant Research, more recently demonstrated in
children and adults with AML with PIF or relapse fol-
lowing alloSCT, an estimated 3-year OS of 19% (95%
CI 17%-21%). In the current study, although small
numbers and a varying dose of GO, there is an
estimated 5-year OS of 50% in this very poor-risk pop-
ulation of children and adolescents with AML.
Adult phase III trials of GO along with induction
chemotherapy demonstrated higher rates of fatal
adverse events, and these events were mostly related
to myelosuppression [32]. GO might be better suited
in the setting of alloSCT as myelosuppression can be
circumvented by a donor stem cell infusion. Surpris-
ingly, a pediatric phase III trial of GO in combination
with induction chemotherapy did not demonstrate an
increase in fatal adverse events related to GO [33].
In summary, we have demonstrated thatGO can be
safely added to a MAC of Bu/Cy in doses 3-7.5 mg/m2
on day214 before alloSCT in children and adolescents
with poor-risk AML. GO in combination with Bu/Cy
was well tolerated, but also resulted in a 5-year OS of
50% in children and adolescents with poor-risk AML.
Although GO has not been demonstrated to be associ-
ated with improved disease-free survival or reinduction
CR in adults with AML in CR1 or following relapse,
respectively [34,35], there may be an important role of
GO as targeted immunotherapy as part of MAC with
Bu/Cy as in the present study or part of post-alloSCT
therapy following reduced-intensity conditioning ther-
apy [36]. However, a number of mechanisms of resis-
tance to GO have been demonstrated [37-41]. Wehave received approval from the Food and Drug
Administration and the manufacturer of GO (Pfizer)
to proceed with a phase II study of GO (7.5 mg/m2
[IND #111024]) on day 214 with similar doses of Bu/
Cy in children, adolescents, and young adults with
poor-risk AML. Ultimately, this targeted immunoche-
motherapyMACmay be incorporated into other AML
patients undergoing alloSCT, such as those with poor-
risk AML in CR1, or those in CR2, and/or those with
minimal residual disease [42,43].ACKNOWLEDGMENTS
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